FUNDING

“We are grateful for the Stage 2 award from MassVentures as we work to bring MyoRegulator® to market,” said Nader Yaghoubi, M.D., Ph.D., Co-Founder and Chief Executive Officer of PathMaker. “As we continue our US multi-center pivotal trial in post-stroke spasticity and work to launch our first clinical trial in ALS this year, MassVentures support for late-stage development of our product is greatly appreciated.”

“There is currently no widely available treatment solution that allows patients to return to a pain-free active lifestyle following meniscectomy,” said Maria Kristina Bartolo, Ph.D., Chief Technology Officer at Orthonika. “We are delighted that Innovate UK has recognised the potential for our novel total meniscus replacement to fulfill a significant unmet clinical need and further promote joint preservation.”

Dr Peter Staats brings extensive expertise to the company and will collaborate with the advisory board and Neuralace Medical to contribute valuable insights and strategic guidance.